media – Page 10 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Novo Nordisk’s “GIP/GLP-1 dual agonist” has been approved for clinical trials in China

According to the CDE official website, Novo Nordisk’s Class 1 new drug NNC0519-0130 injection has obtained implicit approval for clinical trials, and its indication is type 2 diabetes. According to public information, the drug is a GIP/GLP-1 dual agonist. GIP and GLP-1 are two important hormones that regulate blood sugar. The function of GLP-1 is to stimulate insulin secretion and inhibit glucagon secretion; GIP is a dual-function hormone that promotes insulin secretion in high blood sugar and stimulates the release of glucagon in low blood sugar to stabilize blood sugar. Studies have shown that GIP can reduce food intake and increase energy consumption, thereby reducing weight. When GIP is used in combination with GLP-1 receptor agonists, it may have a greater impact on glucose levels and body weight. According to the ClinicalTrials website, Novo Nordisk has launched multiple clinical studies on NNC0519-0130 injection in many places around the world, including ...
- Source: drugdu
- 53
- December 6, 2024
Employee sentenced to 13 years in prison, AstraZeneca insurance fraud storm is not over

From June to September 2024, many cases related to AstraZeneca insurance fraud were sentenced one after another. An operation named “Star Project” by the prosecutor revealed the tip of the iceberg of pharmaceutical representatives tampering with genetic test reports and defrauding medical insurance funds. AstraZeneca, the fastest growing British multinational pharmaceutical company in China and the most watched “sales champion” in the pharmaceutical industry, was exposed to be involved in many “insurance fraud cases”. According to the criminal verdicts obtained by the reporter, in the past three years, there have been many AstraZeneca “insurance fraud cases” that have been tried or sentenced in Shenzhen and Fujian alone, and there are also cases waiting to be heard in Chongqing and Jiangxi. Some people in the pharmaceutical industry pointed out that the AstraZeneca insurance fraud case can be said to be the most shocking event caused by multinational pharmaceutical companies in China ...
- Source: drugdu
- 50
- December 6, 2024
“China’s Multi-Antibody Star” launches IPO

Recently, “China’s multi-antibody star” Welly Zhibo Biotech submitted a prospectus to the Hong Kong Stock Exchange, intending to go public on the main board of Hong Kong through an IPO. This biotech, founded in 2012, had just completed a large NewCo-style BD and also completed a C+ round of financing in November. The latest post-investment valuation has exceeded 3 billion yuan. The latest valuation is over 3 billion. Welly Zhibo’s CEO is Dr. Kang Xiaoqiang, who studied for his master’s degree at Tongji Medical College, and completed his doctoral and postdoctoral studies in the United States. Later, he joined a biotech called ImClone Systems, which became famous for the development of the EGFR monoclonal antibody Erbitux. The drug was launched in 2004, with peak sales of more than 2 billion US dollars, and Kangbo participated in the development and launch of the drug. In 2008, ImClone Systems was acquired by ...
- Source: drugdu
- 56
- December 6, 2024
Sanofi will build a new insulin production base in Beijing

On December 2nd, Beijing welcomed an investment of up to 1 billion euros (approximately 7.66 billion yuan) – the Beijing Municipal Bureau of Economy and Information Technology, the Beijing Economic and Technological Development Zone Management Committee, and multinational pharmaceutical company Sanofi signed a memorandum of cooperation. Sanofi will build a new insulin production base in Yizhuang, and after completion, it will form a full industry chain layout of insulin preparations from raw materials to finished products in Beijing. Sanofi will invest in the construction of the second Beijing production base, improve the local end-to-end production and manufacturing capacity of insulin, and focus on serving the insulin drug demand of local diabetes patients. This will be Sanofi’s fourth production and supply base in China, and also the company’s largest single investment in China. Over the past 40 years of deep cultivation in China, Sanofi has continuously increased its investment in Chinese ...
- Source: drugdu
- 63
- December 5, 2024
Over 1 billion US dollars! Yingen Biotech Innovates Preclinical ADC Drug Authorization GSK

Today (December 4, 2024), Duality Biologics announced that it has reached an exclusive licensing agreement with GlaxoSmithKline (GSK) for an antibody conjugated drug (ADC) DB-1324. According to the agreement, GSK will obtain the exclusive authorization of the world (excluding Chinese Mainland, Hong Kong and Macao) to promote the development and commercialization of the ADC drug. According to the terms of the agreement, GSK will pay $30 million in advance and other pre exercise milestone payments to obtain an exclusive license to promote the R&D and commercialization of DB-1324 worldwide (excluding Chinese Mainland, Hong Kong and Macao). If GSK exercises its licensing rights, Yingen Biotechnology will charge an exercise fee and subsequent milestone payments at different stages of development, regulatory registration, and commercialization, up to a maximum of $975 million. After successful commercialization, GSK will pay different proportions of graded royalties to the global net sales (excluding Chinese Mainland, Hong Kong ...
- Source: drugdu
- 62
- December 5, 2024
GE Healthcare announced that it will acquire the nuclear medicine giant in full.

On December 1, GE Healthcare officially announced that it will acquire the remaining 50% of Nihon Medi-Physics (“NMP”) from Sumitomo Chemical. The transaction is expected to be completed in early 2025. NMP was founded in 1973 and is headquartered in Tokyo, Japan. It was originally jointly established by British life science company Amersham and Sumitomo Chemical. In 2004, GE Healthcare acquired Amersham and thus held a 50% stake in NMP. If this acquisition is completed, GE Healthcare will have full ownership of NMP. GE Healthcare CEO Peter J Arduini shared on LinkedIn: “By wholly owning NMP, which is already a leader in Japan, we will improve patient access to next-generation radiopharmaceuticals to enable disease detection and diagnosis, and make NMP the preferred partner for global innovators seeking to introduce new radiopharmaceuticals to Japan and other Asian markets.” According to public data, NMP directly holds multiple nuclear medicine approvals and occupies ...
- Source: drugdu
- 53
- December 5, 2024
Targeting Parkinson’s disease! Fosun Pharma takes another step

Recently, according to the official website of CDE, the application for the listing of the 5.1 new drug Opicapone Capsules jointly submitted by Fosun Pharma and Bial-Portela & Ca was accepted. According to the information, Opicapone Capsules is an adjuvant treatment drug for primary Parkinson’s disease introduced by Fosun Pharma from Bial-Portela & Ca of Portugal. It is a new generation of catechol-O-methyltransferase inhibitors (COMT) inhibitors. It is worth mentioning that the COMT inhibitors currently approved for listing in China include the first-generation tolcapone and the second-generation entacapone. Compared with the above similar drugs, the third-generation COMT inhibitor Opicapone has shown advantages in terms of effectiveness and safety. Introduced by Fosun, it is expected to be listed in China . At present, there are three COMT inhibitors listed in the world. The COMT inhibitors listed in China include tolcapone and entacapone. In addition, the combination of entacapone and compound levodopa, ...
- Source: drugdu
- 50
- December 5, 2024
Merck’s Injectable Imipenem/Cilastatin Receives Approval in China

Shanghai Securities News – On December 3, Merck announced that its novel carbapenem/enzyme inhibitor combination, injectable imipenem/cilastatin, has been approved by the National Medical Products Administration of China. It is indicated for the treatment of the following infections in patients aged 18 and older caused by sensitive Gram-negative bacteria: hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP); complex urinary tract infections (cUTI) with limited or no alternative treatment options (including pyelonephritis); and complex intra-abdominal infections (cIAI) with limited or no alternative treatment options. It is noted that antibiotic resistance is a significant challenge in the field of global public health. Data from the China Antibacterial Resistance Monitoring Network (CHINET) shows that the incidence of carbapenem-resistant Enterobacteriaceae (CRE) infections in China was 12.5% in 2014, increased to 22.9% in 2016, and rose to 26.8% in 2019. Compared to 2015, the incidence of CRE in China increased by over 58% in 2023. ...
- Source: drugdu
- 48
- December 5, 2024
Hutchmed’s Oral Multi-Target Anti-VEGFR Innovative Drug Fuguetinib Approved in China

On December 3, 2024, Hutchmed announced that its self-developed innovative drug Fuguetinib has been approved by the National Medical Products Administration (NMPA) of China. This drug is to be used in combination with Sintilimab for patients with advanced mismatch repair-proficient (pMMR) endometrial cancer (EMC) who have failed previous systemic anti-tumor therapies and are not suitable for radical surgical treatment or radical radiotherapy. This approval marks the first and only selective inhibitor targeting three VEGFR subtypes in China, granted approval for the treatment of colorectal cancer in the key markets of the U.S., Europe, and Japan in over a decade. In 2024, Fuguetinib, in combination with Sintilimab, received a new indication through the NMPA’s priority review. Currently, traditional treatment for advanced endometrial cancer primarily focuses on surgical intervention, supplemented by systemic treatments such as radiotherapy, chemotherapy, or hormone therapy. For patients who are not suitable candidates for radical surgery, particularly those ...
- Source: drugdu
- 56
- December 5, 2024
MEDICALL EXPO

Organiser：Messe Düsseldorf GmbH (Germany) Time：February 15th – 17th, 2025 Address：84/3, JBS Haldane Ave, Gobra, Tangra, Kolkata, West Bengal 700046 Exhibition hall：Milan Mela Complex Product range: Medical Technology/E-Health Products, Devices, and Systems Zone Diagnostic, Imaging Products, Devices, and Systems Zone Portable Physiotherapy and Orthopedic Products, Devices, and Systems Zone Surgical Products, Devices, and Systems Zone Hygiene and Sterilization Products, Disposable Consumables Zone (Note: The above zones are repeated in the original text, so they are listed once here for clarity.) Rehabilitation Devices and Equipment Zone About MEDICALL EXPO： MEDICALL EXPO is one of the most professional medical equipment exhibitions in India and South Asia. Organized by Messe Düsseldorf GmbH, it is a significant trade show for the Indian hospital and medical device industry. With 750 exhibiting companies from China, the United States, the United Kingdom, Germany, Japan, South Korea, Thailand, Malaysia, Australia, Singapore, and other countries, and attracting 23,000 ...
- Source: drugdu
- 98
- December 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.